High serum level of bioactive interleukin-6 (IL-6) is regarded as a predictor of poor prognosis in multiple myeloma (MM). On the other hand, the reported levels of immunoreactive IL-6 have been highly variable, and the prognostic value of immunoreactive IL-6 in MM is not clear. We have analyzed the prognostic significance of serum immunoreactive IL-6, as measured by a sensitive immunosorbent assay, in 210 patients with newly diagnosed MM subsequently treated with intermittent melphalan and prednisone. The serum levels of acute phase proteins C-reactive protein (CRP), al-antitrypsin (alAT), and acid al-glycoprotein (orosomucoid; OM) were evaluated as surrogates for IL-6. Serum IL-6, CRP, d A T , and OM levels were raised in 42%, M%, 41%, and 24% of the patients, respectively. There was a significant correlation between the clinical stage of the patients and serum IL-6 (P = .006), a l A T (P = .001), and OM ( P = .004) levels at diagnosis. At 3 years, 52% of the patients were alive. Univariate logistic regression analysis showed that
ULTIPLE MYELOMA (MM) is a clonal disorder where terminally differentiated B cells and plasma cells infiltrate the bone marrow, produce the monoclonal Ig, and secrete osteoclast-activating factors leading to bone lesions. The growth of myeloma cells is regulated by a cytokine network where interleukin-6 (E-6) plays a key role.' IL-6 may act as an autocrine2 or paracrine3 growth factor for myeloma cells. Measurements of serum L -6 concentrations by a sensitive bioassay have demonstrated raised levels in about one third of MM patients at diagnosis! High concentration of serum bioactive IL-6 in MM patients has been associated with poor
On the other hand, the reported levels of immunoreactive IL-6 have been varied and even ~ndetectable,~-" and the prognostic significance of immunoreactive IL-6 is, thus, unresolved.
By applying a sensitive enzyme-linked immunosorbent assay (ELISA) we have recently reported raised serum levels of IL-6 in 30% of a small cohort of patients with newly diagnosed ". I2 In the present study, we have analyzed the prognostic significance of immunoreactive IL-6 in 210 patients included in the clodronate study of the Finnish Leukemia Group.I3 As L -6 is a pleiotropic cytokine that, among other functions, induces the synthesis of acute phase proteins in the liver,I4 we also evaluated the prognostic significance of serum C-reactive protein (CRP), al-antitrypsin (alAT), and acid al-glycoprotein (orosomucoid; OM) as surrogates for IL-6. The prognostic significance of IL-6 and acute phase proteins was evaluated together with that of previously established prognostic factors, serum P2-microglobulin (P2M)'5-'7 and thymidine kinase (TK)."
M

MATERIALS AND METHODS
The Finnish Leukemia Group clodronate trial included 350 patients entered between March 1986 and August 1989. The patients were treated with melphalan and prednisone and randomized to receive oral clodronate or placebo. The median survival time, calculated from the onset of chemotherapy, was 36 months for both treathigh levels of 11-6 ( P = .002), CRP (P = .02), a1AT ( P < . O O l ) , OM (P = .007), P2-microglobulin (P2M; P < .001), and thymidine kinase (P < .M) were all associated with 3-year mortality. In multivariate regression analysis, PZM (P < .00011 and a1AT ( P = .01) had independent prognostic significance. The patients with high levels of both P2M and aIAT or IL-6 were at very high risk of dying within 3 years from diagnosis (16% and 21% of the patients in these groups were alive, respectively). When the patients were stratified according to the clinical stage, the prognostic significance of serum IL-6 and a l A T was especially evident in stage I1 patients. When the patients were divided into two groups according t o normal or raised serum IL-6 levels, the patients with high 11-6 levels had more frequent osteolytic bona lesions ( P = .03) and a more aggreasive disease. We conclude that serum immunoreactive 11-6 is a significant prognostic marker in MM. 8 1995 by The American Society of Hematology. ment arms. A serum sample drawn at diagnosis was available in 210 of these patients, and these patients form the study group for this investigation.
The median age of the patients in the study group was 68 years (range, 25 to 89 years). There were 102 males and 108 females. The paraprotein heavy chain was IgG in 143 patients (68.1%), IgA in 42 (20.0%), and IgD in one (0.5%). Twenty patients (9.5%) had light chain disease, and four (1.9%) were nonsecretory. Clinical stage according to Dune and Salmon'' was distributed as follows: stage IA, 26.6%; IIA, 43.2%; IIB, 5.6%; IIIA, 18.0%; and IIIB, 6.6%. Lytic bone lesions were found at diagnosis in 66% of the patients. All of the patients have been observed for 3 years or until death. At 3 years, 109 patients (52%) were alive.
Serum samples were drawn at diagnosis, stored frozen, and after thawing, clarified by centrifugation (Beckman Airfuge Ultracentrifuge; Beckman Instruments Inc, Palo Alto, CA). L 6 concentration was measured by a sensitive sandwich-type ELISA (Quantikine; R& D Systems, Minneapolis, MN), with a detection limit of 0.4 ng/L and upper reference limit of 3.2 ng/L in 35 healthy controls (range, less than 0.4 to 3.2 ng/L; median, 1.4 ng/L). CRP was measured by particle-enhanced nephelometry (NA Latex CRP Kit; Behringwerke AG, Marburg, Germany), and alAT, OM, and a2-macroblobulin 766 
RESULTS
Serum concentrations of IL-6 and acute phase proteins.
The serum concentration of immunoreactive IL-6 was above the upper reference limit of the healthy controls in 42% of the MM patients at diagnosis (Table l) . Regarding acute phase proteins, serum CRP level was above 6 m&, the prognostic cut-off level in earlier studies,"." in 40% of the patients. The other two acute phase proteins, a l A T (upper reference limit, 2.7 g L ) and OM (upper reference limit, 1.5 g/L), were raised in 41% and 24% of the patients, respectively. Serum albumin was decreased in 21% of the patients.
The distribution curves for IL-6 and CRP levels were strongly skewed, as indicated by the discrepancy between the mean and median values (Table 1) . Therefore, in the (n = 100)
Mean ,171
For analysis of variance, IL-6 and CRP were logarithmically (base e) transformed. The number of patients was 209.
linear regression analyses the values for IL-6 and CRP, as well as for P2M and TK, were logarithmically (In) transformed. Among the acute phase proteins, Cl" showed the strongest correlation with serum IL-6 concentration (Table 2).
When the patients were stratified according to the clinical stage, a significant correlation could be shown between the stage and serum levels of L-6, alAT, and OM, but not between clinical stage and serum CRP or albumin (Table 3) .
Survival. The median survival time of the 350 patients entering the Finnish Leukemia Group clodoronate study was 36 months, and 52% of the 210 patients included in this analysis were alive at 3 years. The common risk factors that might predict the 3-year mortality in MM are listed in Table  4 . The patients who survived 3 years were younger, had lower serum creatinine, urate, and calcium concentrations, Values are medians (ranges).
and higher blood hemoglobin levels than the patients who died during the 3-year follow-up. Serum concentrations of immunoreactive IL-6 and acute phase proteins (CRP, alAT, and OM) were significantly higher in the patients who had died during the 3-year follow-up as compared with those who were alive at 3 years (Table 5 ). The level of a2M, a suggested carrier for IL-6," was not different between the two groups (median values, 2.4 g/L and 2.5 g/L for the patients who were alive or had died at 3 years, respectively; P = .67). The serum concentrations of P2M and TK were also higher in the patients who had died during the 3-year observation period (Table 5 ). In univariate logistic regression analysis, serum concentrations of immunoreactive IL-6, acute phase proteins (CRP, a1AT and OM), P2M, and TK were all statistically significant predictors of 3-year mortality (Table 6 ). In multivariate logistic regression analysis with IL-6, P2M, TK, CRP (all four logarithmically transformed), a 1 AT, and OM as covariates, P2M and a 1 AT were statistically significant independent predictors of 3-year mortality (Table 7) . If age, blood hemoglobin level, and serum creatinine, urate, and calcium concentrations were also included in the multivariate analysis, P2M (P = .006), calcium ( P = .013), and a l A T (P = .05) had statistical or borderline significance. When the patients were divided in two groups according to the serum IL-6 or a l A T levels at diagnosis, a significant survival benefit was seen for the patients with low levels of IL-6 (Fig 1) or a l A T (Fig 2) , respectively. When the patients were stratified in four groups according to serum P2M and IL-6 levels (Fig 3) or P2M and a l A T levels (Fig 4) , those with high levels for both P2M and IL-6 or P2M and a1AT were high-risk patients, with only 21% and 16% surviving at 3 years, respectively. If the patients were stratified in three groups according to the clinical stage, the prognostic significance of IL-6 (Fig 5) and a1AT (Fig 6) was especially seen in stage I1 patients (stage 11, high v low L -6 levels, P = .0004; stage 11, high v low a l A T levels, P = .0002, respectively).
Distribution of other prognostic factors according to se-
rum ZL-6 concentration. Several possible prognostic parameters were compared in the two patient groups defined according to normal or raised serum IL-6 concentration (Table 8). Patients with raised serum IL-6 levels were older and had more advanced disease, more frequent osteolytic lesions, lower blood hemoglobin and serum albumin levels, and higher serum creatinine, urate, and calcium concentrations. Also the serum levels of P2M and acute phase proteins were higher in the patients with raised IL-6 levels, whereas serum TK concentration was not significantly different between the two groups. For personal use only. on November 11, 2017. by guest www.bloodjournal.org From cantly improved the outcome of MM patients. Intensive treatment including rescue by autologous bone marrow or peripheral blood stem cell transplantation is a new promising option in the management of MM. To offer the patients an appropriate treatment modality and to correctly stratify patients in clinical trials, careful analysis of prognostic factors is mandatory. In the Finnish Leukemia Group clodronate trial, all patients were primarily treated with melphalan and prednisone, and thus, this cohort of myeloma patients allowed us to evaluate the prognostic significance of various pretreatment characteristics.
As IL-6 plays a key role in the cytokine network regulating For personal use only. on November 11, 2017. by guest www.bloodjournal.org From present study increased levels of serum IL-6 in 42% of patients with newly diagnosed MM. The range of serum IL-6 concentrations and the proportion of MM patients with increased IL-6 levels agree well with the bioassay r e s~l t s .~ As IL-6 induces the synthesis of acute phase proteins in the liver,14.z6*z7 the serum levels of acute phase proteins might serve as surrogates for IL-6 activity in vivo.',zo The close correlation between IL-6 activity and the serum concentration of acute phase proteins is supported by the finding that in vivo administration of anti-IL-6 antibody causes a rapid decrease2' and administration of recombinant IL-6 a sharp increasez9 in serum C m concentration. The results in our MM patients show that serum IL-6 level correlates with the concentration of acute phase proteins and that the correlation was strongest with CRP. A correlation between the serum levels of CRP and bioactive IL-6 has previously been documented in severe burns3' and rheumatoid arthriti~.~' Several pretreatment characteristics, eg, age, hemoglobin level, stage of the disease, renal function, P2M concentration, and plasma cell labeling index, give prognostic informamass and renal function is usually regarded as the most significant single prognostic factor in MM.I5-l7 Also, in our patients P2M level was strongly associated with survival and came out first in the multivariate analysis. Previous studies have resulted in contrasting data about the value of other prognostic parameters in addition to P2M. Bataille et alZo showed that serum CRP level gave prognostic information in addition to P2M and proposed a stratification system based on P2M and CRP levels. Merlini et a134 confirmed the prognostic significance of acute phase proteins, but in their study, a1AT was more powerful than CRP. Greipp et a121 reported that CRP was a significant prognostic marker, but in the multivariate analysis, only plasma cell labeling index tion in MM.l5.16.l9.32,~3 Serum P2M level reflecting the tumor and P2M had independent prognostic significance. In the present study, plasma cell labeling index was not measured, but we assayed instead the activity of TK, which is an enzyme involved in cell proliferation. Serum levels of TK are increased in MM patients who also have high plasma cell labeling index and poor p r o g n~s i s , "~~~~~~ and TK may provide additional prognostic information after P2M stratification in melphalan-treated MM patients." Our results in 210 melphalan-treated patients show that immunoreactive IL-6, P2M, and TK are significant prognostic markers in MM. When these three parameters together with the acute phase proteins were included in the multivariate analysis, P2M and a l A T (but not TK) had independent prognostic value. Thus, serum alAT, reflecting the biologic effects of IL-6, provides additional prognostic information to the tumor mass and renal function represented by serum P2M. This result agrees with the earlier observation that among acute phase proteins, a1AT had the strongest correlation with survival.34 However, stratification of the patients according to the clinical stage showed that the prognostic significance of IL-6 and a1AT was concentrated in stage I1 patients. In agreement with the results of Bataille et a12" on serum P2M and CRP levels, we also found that a powerful prognostic stratification of myeloma patients can be based on serum levels of P2M and either IL-6 or a 1 AT.
Stratification of the MM patients into two groups with either normal or raised serum IL-6 concentration showed that several other prognostic factors were associated with the IL-6 level. The lower serum albumin concentrations in patients with raised IL-6 levels is in agreement with the For personal use only. on November 11, 2017. by guest www.bloodjournal.org From
